Natacha Joyon

Natacha Joyon

Auto-generated profile, based on publicly available information

Natacha Joyon

Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
TGThomas Grinda
Thomas Grinda
NJNatacha Joyon
Natacha Joyon
ALAmélie Lusque
Amélie Lusque
SLSarah Lefèvre
Sarah Lefèvre
LALaurent Arnould
Laurent Arnould
MLMagali Lacroix-Triki
Magali Lacroix-Triki
Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.

16 March 2023 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
GGGrégoire Gessain
Grégoire Gessain
NJNatacha Joyon
Natacha Joyon
TPThomas Petit
Thomas Petit
SCSophie Cotteret
Sophie Cotteret
MLMagali Lacroix-Triki
Magali Lacroix-Triki

16 June 2022 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NJNatacha Joyon
Natacha Joyon
ZGZoe Guillaume
Zoe Guillaume
LOLamia Ouafi
Lamia Ouafi
SCSophie Cotteret
Sophie Cotteret
EREtienne Rouleau
Etienne Rouleau
MLMagali Lacroix-Triki
Magali Lacroix-Triki

29 May 2022 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NJNatacha Joyon
Natacha Joyon
MMMarie-Christine Mathieu
Marie-Christine Mathieu
EREtienne Rouleau
Etienne Rouleau
ARAurélie Roulot-Paumelle
Aurélie Roulot-Paumelle
JSJean-Yves Scoazec
Jean-Yves Scoazec
VSVoichita Suciu
Voichita Suciu
Mammary pleomorphic adenoma is a biphasic tumor, characterized by epithelial-myoepithelial components with myxochondroid stroma, resembling the prototypic pleomorphic adenoma of the salivary glands. We report the multiple diagnostic pitfalls raised by a mammary pleomorphic adenoma, initially diagnosed as mucinous carcinoma on fine-needle aspiration (FNA) cytology and invasive carcinoma on needle core biopsy. The final diagnosis was made on the surgical specimen. As the term “pleomorphic” suggests, this tumor can present various phenotypes, some of which might be misleading on both FNA cytology or needle core biopsy. Rearrangements in PLAG1 and HMGA2 genes have not been detected in our patient. Mammary pleomorphic adenoma is considered a benign tumor, despite rare local recurrence and malignant behavior. Its correct identification, despite the difficulties, is essential to avoid unnecessary aggressive treatment.

1 April 2021 in Annales de Pathologie
Verified
Journal Article
Closed access
VLValentine Langlois
Valentine Langlois
NJNatacha Joyon
Natacha Joyon
RFRita Bou Farah
Rita Bou Farah
ECElisabeth Chachaty
Elisabeth Chachaty
JSJean-Yves Scoazec
Jean-Yves Scoazec

1 March 2021 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
NJNatacha Joyon
Natacha Joyon
CKChristina Kanaan
Christina Kanaan
SCSophie Cotteret
Sophie Cotteret
ISIsabelle Sourrouille
Isabelle Sourrouille
JSJean-Yves Scoazec
Jean-Yves Scoazec
PDPeggy Dartigues
Peggy Dartigues